HK1060726A1 - Vla-4 inhibitors - Google Patents
Vla-4 inhibitorsInfo
- Publication number
- HK1060726A1 HK1060726A1 HK04103218.6A HK04103218A HK1060726A1 HK 1060726 A1 HK1060726 A1 HK 1060726A1 HK 04103218 A HK04103218 A HK 04103218A HK 1060726 A1 HK1060726 A1 HK 1060726A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vla
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000402890 | 2000-12-28 | ||
JP2001149923 | 2001-05-18 | ||
PCT/JP2001/011641 WO2002053534A1 (fr) | 2000-12-28 | 2001-12-28 | Inhibiteurs de vla-4 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1060726A1 true HK1060726A1 (en) | 2004-08-20 |
Family
ID=26607210
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04103218.6A HK1060726A1 (en) | 2000-12-28 | 2004-05-07 | Vla-4 inhibitors |
HK06101636.2A HK1081545A1 (en) | 2000-12-28 | 2006-02-08 | Vla-4 inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06101636.2A HK1081545A1 (en) | 2000-12-28 | 2006-02-08 | Vla-4 inhibitors |
Country Status (17)
Country | Link |
---|---|
US (1) | US7157487B2 (ru) |
EP (1) | EP1346982B1 (ru) |
JP (1) | JP4212358B2 (ru) |
KR (1) | KR100884877B1 (ru) |
CN (1) | CN100471838C (ru) |
AR (1) | AR035218A1 (ru) |
AT (1) | ATE524441T1 (ru) |
AU (1) | AU2002219555B2 (ru) |
BR (1) | BR0116608A (ru) |
CA (1) | CA2430978C (ru) |
HK (2) | HK1060726A1 (ru) |
IL (1) | IL156064A0 (ru) |
MX (1) | MXPA03005838A (ru) |
NO (1) | NO326014B1 (ru) |
RU (1) | RU2290403C2 (ru) |
TW (1) | TWI312779B (ru) |
WO (1) | WO2002053534A1 (ru) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0031315D0 (en) * | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
EP1499311B1 (en) | 2002-03-29 | 2009-11-04 | Novartis Vaccines and Diagnostics, Inc. | Substituted benzazoles and use thereof as raf kinase inhibitors |
ATE374768T1 (de) | 2002-10-03 | 2007-10-15 | Hoffmann La Roche | Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren |
US20070066577A1 (en) * | 2003-04-03 | 2007-03-22 | Hea Young Park Choo | Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same |
WO2004099136A1 (ja) * | 2003-05-09 | 2004-11-18 | Daiichi Pharmaceutical Co., Ltd. | ピロリジン誘導体の製造方法 |
EP1479675A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
TWI340134B (en) | 2003-07-24 | 2011-04-11 | Daiichi Seiyaku Co | Cyclohexanecarboxylic acids |
US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
US20070149606A1 (en) * | 2003-12-26 | 2007-06-28 | Daiichi Pharmaceutical Co.,Ltd. | Process for producing phenylacetic acid derivative |
WO2005066124A1 (ja) * | 2003-12-26 | 2005-07-21 | Daiichi Pharmaceutical Co., Ltd. | ピロリジン誘導体の製造法 |
RU2393154C2 (ru) * | 2004-03-24 | 2010-06-27 | Йерини Аг | Новые соединения для ингибирования ангиогенеза и их применение |
JP2005350417A (ja) * | 2004-06-11 | 2005-12-22 | Dai Ichi Seiyaku Co Ltd | 還元的エーテル化法を用いたピロリジン誘導体の製造法 |
TW200610754A (en) * | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
EP1771169A1 (en) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
AU2005275182A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating Hepatitis C |
JP2006056830A (ja) * | 2004-08-20 | 2006-03-02 | Dai Ichi Seiyaku Co Ltd | 2−アリールアミノベンゾオキサゾール誘導体 |
WO2006068760A2 (en) * | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
RU2415846C2 (ru) * | 2005-08-26 | 2011-04-10 | Шионоги энд Ко., Лтд | Производные, имеющие активность агонистов ppar-рецепторов |
EP1961750B1 (en) * | 2005-12-13 | 2013-09-18 | Daiichi Sankyo Company, Limited | Vla-4 inhibitory drug |
WO2008127226A2 (en) * | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | P13 kinase antagonists |
DE102006021878A1 (de) * | 2006-05-11 | 2007-11-15 | Sanofi-Aventis | Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7858645B2 (en) * | 2006-11-01 | 2010-12-28 | Hoffmann-La Roche Inc. | Indazole derivatives |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
JP5547099B2 (ja) * | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
CA2747252C (en) | 2008-12-19 | 2018-09-18 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2010144550A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
WO2010144394A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
ES2557453T3 (es) | 2009-06-09 | 2016-01-26 | Nantbioscience, Inc. | Derivados de isoquinolina, quinolina y quinazolina como inhibidores de la señalización de Hedgehog |
US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR101875720B1 (ko) | 2011-01-10 | 2018-07-09 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
CN106619647A (zh) | 2011-02-23 | 2017-05-10 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
KR20140063605A (ko) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
EP2900673A4 (en) | 2012-09-26 | 2016-10-19 | Univ California | MODULATION OF IRE1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3052485B1 (en) | 2013-10-04 | 2021-07-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2016071499A1 (en) * | 2014-11-06 | 2016-05-12 | Basf Se | 3-pyridyl heterobicyclic compound for controlling invertebrate pests |
PT3307734T (pt) | 2015-06-09 | 2020-02-25 | Abbvie Inc | Moduladores de recetores nucleares (ror) para o tratamento de doenças inflamatórias e autoimunes |
EP3350183A1 (en) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
EP3873884A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
JP7491996B2 (ja) | 2019-08-14 | 2024-05-28 | ギリアード サイエンシーズ, インコーポレイテッド | α4β7インテグリンの阻害のための化合物 |
EP4165037A1 (en) | 2020-06-10 | 2023-04-19 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
EP4284947A1 (en) | 2021-01-29 | 2023-12-06 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
KR20240035513A (ko) | 2021-07-09 | 2024-03-15 | 알리고스 테라퓨틱스 인코포레이티드 | 항바이러스 화합물 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
DE2706977A1 (de) * | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
US4184658A (en) | 1978-02-13 | 1980-01-22 | General Electric Company | Cushion mount for prime mover |
DE3063878D1 (en) | 1979-07-13 | 1983-07-28 | Thomae Gmbh Dr K | Derivatives of carboxylic acids, their preparation and medicaments containing them |
JPS60181081A (ja) * | 1984-02-29 | 1985-09-14 | Kaken Pharmaceut Co Ltd | 新規ビスベンゾフラニルケトン誘導体 |
JPH04112868A (ja) * | 1990-09-03 | 1992-04-14 | Otsuka Pharmaceut Co Ltd | 置換ヘテロ環を有するフェニルカルボン酸誘導体 |
JPH0543574A (ja) | 1991-08-13 | 1993-02-23 | Wakamoto Pharmaceut Co Ltd | ヘテロ環置換テトラゾール−1−酢酸誘導体 |
FR2694295B1 (fr) * | 1992-07-28 | 1994-09-02 | Adir | Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent. |
US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
ES2103181B1 (es) | 1994-08-01 | 1998-04-01 | Menarini Lab | Amidas naftalenicas con accion antagonista de los leucotrienos. |
GB9408936D0 (en) | 1994-05-05 | 1994-06-22 | Cancer Res Inst | Anti-cancer compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
EP0835104A4 (en) | 1995-06-30 | 1999-10-20 | Smithkline Beecham Corp | USE OF STAT 5 SH2 DOMAINE SPECIFIC COMPOUNDS TO PROMOTE ERYTHROPOSIS |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
CZ298089B6 (cs) | 1996-07-25 | 2007-06-20 | Biogen Idec Ma Inc. | Inhibitory bunecné adheze, zpusob jejich prípravya farmaceutické prostredky s jejich obsahem |
WO1998008818A1 (en) | 1996-08-26 | 1998-03-05 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
HUP0000492A3 (en) * | 1996-11-22 | 2000-06-28 | Lilly Co Eli | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
US6117901A (en) | 1996-11-22 | 2000-09-12 | Athena Neurosciences, Inc. | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use |
WO1999033789A1 (en) | 1997-12-23 | 1999-07-08 | Aventis Pharma Limited | SUBSTITUTED β-ALANINES |
AU3297099A (en) * | 1998-02-25 | 1999-09-15 | Genetics Institute Inc. | Inhibitors of phospholipase a2 |
PL198189B1 (pl) | 1998-05-28 | 2008-06-30 | Biogen Idec Ma | (R)-N-{[4-{[(2-metylofenyloamino)-karbonylo]amino}fenylo]acetylo}-L-prolilo-3-metylo]-ß-alanina, jej zastosowanie i kompozycja farmaceutyczna ją zawierająca |
CN1311771A (zh) * | 1998-06-08 | 2001-09-05 | 味之素株式会社 | 苯甲脒衍生物 |
BR9911701A (pt) | 1998-06-30 | 2001-03-20 | Pfizer Prod Inc | Inibidores não peptidila da ligação à célula dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias |
EP1133484A2 (en) * | 1998-07-23 | 2001-09-19 | AstraZeneca AB | Heterocyclic derivatives and their use as integrin inhibitors |
GB9916374D0 (en) | 1998-07-23 | 1999-09-15 | Zeneca Ltd | Chemical compounds |
EP1114028B1 (en) | 1998-08-26 | 2006-11-29 | Aventis Pharma Limited | Aza-bicycles which modulate the inhibition of cell adhesion |
GB9821199D0 (en) * | 1998-09-30 | 1998-11-25 | Glaxo Group Ltd | Chemical compounds |
US6207700B1 (en) | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
DE60027700T2 (de) | 1999-02-16 | 2007-05-03 | Aventis Pharma Ltd., West Malling | Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden |
JP2000344666A (ja) | 1999-04-01 | 2000-12-12 | Sankyo Co Ltd | 糖及び脂質代謝改善剤 |
ATE286896T1 (de) | 1999-04-12 | 2005-01-15 | Aventis Pharma Ltd | Substituierte bicyclische heteroaryl-verbindungen als integrin antagonisten |
JP2002543129A (ja) | 1999-05-05 | 2002-12-17 | メルク エンド カムパニー インコーポレーテッド | 抗微生物剤としての新規なプロリン類 |
EP1177181B1 (en) | 1999-05-05 | 2009-01-28 | Aventis Pharma Limited | Substituted bicyclic compounds |
WO2000068195A2 (en) | 1999-05-05 | 2000-11-16 | Aventis Pharma Limited | Substituted pyrrolidines as cell adhesion inhibitors |
DE60009480T2 (de) | 1999-05-05 | 2005-09-01 | Aventis Pharma Ltd., West Malling | Harnstoffe als modulatoren der zelladhäsion |
IL146288A0 (en) | 1999-06-30 | 2002-07-25 | Daiichi Seiyaku Co | Vla-4 inhibitor compounds |
US6756378B2 (en) * | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
JP2003506491A (ja) | 1999-08-13 | 2003-02-18 | バイオジェン インコーポレイテッド | 細胞接着インヒビター |
EP1263726B1 (en) | 1999-11-10 | 2007-09-26 | Sanofi-Aventis Deutschland GmbH | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa |
BR0016818A (pt) | 1999-12-28 | 2002-10-01 | Pfizer Prod Inc | Inibidores não-peptidila de adesão celular dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias |
GB0001346D0 (en) | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
GB0004686D0 (en) | 2000-02-28 | 2000-04-19 | Aventis Pharma Ltd | Chemical compounds |
AU2001235806A1 (en) | 2000-03-01 | 2001-09-12 | Aventis Pharma Limited | 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
JP4068452B2 (ja) | 2000-07-19 | 2008-03-26 | エフ.ホフマン−ラ ロシュ アーゲー | エンドセリン変換酵素阻害剤としてのピロリジン誘導体 |
GB2377933A (en) | 2001-07-06 | 2003-01-29 | Bayer Ag | Succinic acid derivatives useful as integrin antagonists |
-
2001
- 2001-12-28 RU RU2003123115/04A patent/RU2290403C2/ru active
- 2001-12-28 AU AU2002219555A patent/AU2002219555B2/en not_active Ceased
- 2001-12-28 EP EP01272548A patent/EP1346982B1/en not_active Expired - Lifetime
- 2001-12-28 AR ARP010106105A patent/AR035218A1/es unknown
- 2001-12-28 WO PCT/JP2001/011641 patent/WO2002053534A1/ja active Application Filing
- 2001-12-28 CA CA2430978A patent/CA2430978C/en not_active Expired - Fee Related
- 2001-12-28 MX MXPA03005838A patent/MXPA03005838A/es active IP Right Grant
- 2001-12-28 JP JP2002554653A patent/JP4212358B2/ja not_active Expired - Fee Related
- 2001-12-28 AT AT01272548T patent/ATE524441T1/de not_active IP Right Cessation
- 2001-12-28 TW TW090133464A patent/TWI312779B/zh not_active IP Right Cessation
- 2001-12-28 IL IL15606401A patent/IL156064A0/xx unknown
- 2001-12-28 BR BR0116608-5A patent/BR0116608A/pt not_active IP Right Cessation
- 2001-12-28 KR KR1020037008702A patent/KR100884877B1/ko not_active IP Right Cessation
- 2001-12-28 US US10/451,159 patent/US7157487B2/en not_active Expired - Fee Related
- 2001-12-28 CN CNB018214843A patent/CN100471838C/zh not_active Expired - Fee Related
-
2003
- 2003-06-27 NO NO20032994A patent/NO326014B1/no not_active IP Right Cessation
-
2004
- 2004-05-07 HK HK04103218.6A patent/HK1060726A1/xx not_active IP Right Cessation
-
2006
- 2006-02-08 HK HK06101636.2A patent/HK1081545A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20032994D0 (no) | 2003-06-27 |
AU2002219555B2 (en) | 2006-11-30 |
EP1346982A4 (en) | 2005-08-10 |
JPWO2002053534A1 (ja) | 2004-04-30 |
NO326014B1 (no) | 2008-09-01 |
AR035218A1 (es) | 2004-05-05 |
HK1081545A1 (en) | 2006-05-19 |
RU2290403C2 (ru) | 2006-12-27 |
TWI312779B (ru) | 2009-08-01 |
KR20030067730A (ko) | 2003-08-14 |
CN1483024A (zh) | 2004-03-17 |
NO20032994L (no) | 2003-08-27 |
ATE524441T1 (de) | 2011-09-15 |
BR0116608A (pt) | 2004-06-29 |
MXPA03005838A (es) | 2003-09-10 |
EP1346982A1 (en) | 2003-09-24 |
US20040110945A1 (en) | 2004-06-10 |
US7157487B2 (en) | 2007-01-02 |
CA2430978A1 (en) | 2002-07-11 |
IL156064A0 (en) | 2003-12-23 |
WO2002053534A8 (fr) | 2002-09-19 |
EP1346982B1 (en) | 2011-09-14 |
RU2003123115A (ru) | 2005-03-27 |
CA2430978C (en) | 2012-05-15 |
KR100884877B1 (ko) | 2009-02-23 |
CN100471838C (zh) | 2009-03-25 |
JP4212358B2 (ja) | 2009-01-21 |
WO2002053534A1 (fr) | 2002-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1081545A1 (en) | Vla-4 inhibitors | |
AU2002219555A1 (en) | VLA-4 Inhibitors | |
GB9900416D0 (en) | Inhibitors | |
IL146518A0 (en) | Metalloprotease inhibitors | |
IL146288A0 (en) | Vla-4 inhibitor compounds | |
PL356559A1 (en) | 2-guanidino-4-arylchinazolines as nhe-3 inhibitors | |
PL350452A1 (en) | Dihetero-substituted metalloprotease inhibitors | |
HK1042695A1 (zh) | 蛋白酶抑制劑 | |
HK1059260A1 (en) | Farnesyltransferase inhibitors | |
EP1229912A4 (en) | PROTEASE INHIBITORS | |
EP1231921A4 (en) | PROTEASE INHIBITORS | |
EP1229915A4 (en) | PROTEASE INHIBITORS | |
EP1229914A4 (en) | PROTEASE INHIBITORS | |
EP1229911A4 (en) | PROTEASE INHIBITORS | |
EP1173429A4 (en) | PROTEASE INHIBITORS | |
EP1161237A4 (en) | PROTEASE INHIBITORS | |
GB2389113B (en) | B-secretase inhibitor | |
GB0229613D0 (en) | Biocatalyst inhibitors | |
GB0014861D0 (en) | Novel telomerase inhibitors | |
GB0000829D0 (en) | Growth inhibitor | |
GB0015996D0 (en) | Inhibitors | |
GB0021193D0 (en) | Inhibitors | |
GB0029730D0 (en) | Inhibitors | |
GB0029733D0 (en) | Inhibitors | |
GB0005017D0 (en) | Inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20141228 |